Cargando…

4-1BB: A promising target for cancer immunotherapy

Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Alyssa Min Jung, Nemeth, Macy Rose, Lim, Seung-Oe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515902/ https://www.ncbi.nlm.nih.gov/pubmed/36185242 http://dx.doi.org/10.3389/fonc.2022.968360

Ejemplares similares

N-Glycosylation Facilitates 4-1BB Membrane Localization by Avoiding Its Multimerization
por: Sun, Ruoxuan, et al.
Publicado: (2022)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
por: Wang, Ya-Tao, et al.
Publicado: (2022)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy
por: Cong, Yizi, et al.
Publicado: (2021)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
por: Zhang, Wei, et al.
Publicado: (2021)

The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy
por: Akter, Zakia, et al.
Publicado: (2023)

Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells
por: Forster, Stefan, et al.
Publicado: (2020)

Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
por: Cai, Huazhong, et al.
Publicado: (2023)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
por: Wei, Cheng, et al.
Publicado: (2022)

A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer
por: Li, Yuansen, et al.
Publicado: (2022)

Glycosylation of Immune Receptors in Cancer
por: Sun, Ruoxuan, et al.
Publicado: (2021)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
por: Peng, Xiaozhen, et al.
Publicado: (2021)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities
por: Saddawi-Konefka, Robert, et al.
Publicado: (2021)

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
por: Le Bourgeois, Thibault, et al.
Publicado: (2018)

Dickkopf-1: A Promising Target for Cancer Immunotherapy
por: Chu, Hang Yin, et al.
Publicado: (2021)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

Skp2 is a Promising Therapeutic Target in Breast Cancer
por: Wang, Zhiwei, et al.
Publicado: (2012)

Aurora-A Kinase as a Promising Therapeutic Target in Cancer
por: D’Assoro, Antonino B., et al.
Publicado: (2016)

Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
por: Wang, Hao-fan, et al.
Publicado: (2019)

T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
por: Zhou, Qi, et al.
Publicado: (2020)

Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer
por: Nuñez-Olvera, Stephanie I., et al.
Publicado: (2019)

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach
por: Zhang, He, et al.
Publicado: (2021)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
por: Warmuth, Stefan, et al.
Publicado: (2021)

Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy
por: Kawakami, Yutaka, et al.
Publicado: (2013)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Antibody-based cancer immunotherapy by targeting regulatory T cells
por: Li, Quanxiao, et al.
Publicado: (2023)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_flllni12j26o74nchc8ibsleco